长期氧疗联合舒利迭对重度慢性阻塞性肺疾病BODE指数及生活质量的影响

目的:观察长期氧疗(LTOT)联合吸入舒利迭(沙美特罗/氟替卡松,50μg/500μg)对重度慢性阻塞性肺疾病(COPD)患者的BODE指数及生活质量的影响。方法:30例重度COPD患者,在治疗病情稳定后(入组时)回顾性分析入组前6个月COPD急性加重的次数,予以LTOT联合吸入舒利迭,观察入组时与治疗6月后患者的Pa O2、BODE指数、SAS评分、SDS评分、COPD评估测试量表(CAT)评分的变化及记录治疗6月COPD急性加重的次数。结果:患者Pa O2、BODE指数、SAS评分、SDS评分、CAT评分较治疗前明显改善,COPD急性加重的次数明显减少(P<0.05)。结论:LTOT联合吸入舒利迭能改善重度COPD患者Pa O2、BODE指数、心理状况及生活质量,减少COPD急性加重的次数。

Effects of long-term oxygen therapy with Seretide on the BODE index and life quality of severe COPD patients

Objective：To observe the effects of combined long-term oxygen therapy（LTOT） with Seretide inhaler（Salmeterol/fluticasone：50 μg/500 μg） on the indexes of body-mass,airflow obstruction,dyspnea,and exercise（BODE index） and quality of life of patients with severe chronic obstructive pulmo-nary disease（ COPD） .Methods：The exacerbation frequencies were retrospectively analyzed in 30 severe COPD patients six months before and after medi-cation with the previous therapy regimen regarding the PaO2,BODE indexes,scoring on the Self-Rating Anxiety Scale（SAS）,Self-Rating Depression Scale （ SDS） and COPD Assessment Test（ CAT） .Results：The patients were significantly improved in their PaO 2 ,BODE indexes,and scores on SAS,SDS and CAT,and the COPT exacerbation frequencies were significantly decreased after combined medication（P〈0.05）.Conclusion：LTOT with Seretide inhaler may not only improve the PaO2,BODE indexes,mental health status and quality of life for patients with COPD ,but reduce the exacerbation degree of COPD.